Related references
Note: Only part of the references are listed.Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia
Natalia Baran et al.
NATURE COMMUNICATIONS (2022)
Novel mitochondria-targeting compounds selectively kill human leukemia cells
Svetlana B. Panina et al.
LEUKEMIA (2022)
Detection of early seeding of Richter transformation in chronic lymphocytic leukemia
Ferran Nadeu et al.
NATURE MEDICINE (2022)
Glutaminase inhibition with telaglenastat (CB-839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models
Christina A. Wicker et al.
CANCER LETTERS (2021)
Mitochondrial Reactive Oxygen Species and Their Contribution in Chronic Kidney Disease Progression Through Oxidative Stress
Hasna Tirichen et al.
FRONTIERS IN PHYSIOLOGY (2021)
The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma
Ethan Emberley et al.
PLOS ONE (2021)
A comparative pharmaco-metabolomic study of glutaminase inhibitors in glioma stem-like cells confirms biological effectiveness but reveals differences in target-specificity
Katharina Koch et al.
CELL DEATH DISCOVERY (2020)
Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase inhibition-resistant triple-negative breast cancer cells
Larissa Menezes dos Reis et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma
Liang Zhang et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies
Romain Guieze et al.
CANCER CELL (2019)
Assessing Metabolic Intervention with a Glutaminase Inhibitor in Real-Time by Hyperpolarized Magnetic Resonance in Acute Myeloid Leukemia
Niki M. Zacharias et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Interim Analysis of a Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with Azacitidine in Advanced Myelodysplastic Syndrome (MDS)
Veronica A. Guerra et al.
BLOOD (2019)
Del11q-positive CLL lymphocytes exhibit altered glutamine metabolism and differential response to GLS1 and glucose metabolism inhibition
Gabriela Galicia-Vazquez et al.
BLOOD CANCER JOURNAL (2018)
Biological and metabolic effects of IACS-010759, an OxPhos inhibitor, on chronic lymphocytic leukemia cells
Hima V. Vangapandu et al.
Oncotarget (2018)
Ibrutinib Resistance Is Reduced by an Inhibitor of Fatty Acid Oxidation in Primary CLL Lymphocytes
Gabriela Galicia-Vazquez et al.
FRONTIERS IN ONCOLOGY (2018)
BCL2 and miR-15/16: from gene discovery to treatment
Yuri Pekarsky et al.
CELL DEATH AND DIFFERENTIATION (2018)
The p53 family orchestrates the regulation of metabolism: physiological regulation and implications for cancer therapy
Marco Napoli et al.
BRITISH JOURNAL OF CANCER (2017)
B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia
Hima V. Vangapandu et al.
MOLECULAR CANCER RESEARCH (2017)
Glutamine metabolism regulates autophagy-dependent mTORC1 reactivation during amino acid starvation
Hayden Weng Siong Tan et al.
NATURE COMMUNICATIONS (2017)
Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells
Ravyn M. Thompson et al.
ONCOTARGET (2017)
Combenefit: an interactive platform for the analysis and visualization of drug combinations
Giovanni Y. Di Veroli et al.
BIOINFORMATICS (2016)
Alterations of mitochondrial biogenesis in chronic lymphocytic leukemia cells with loss of p53
Marcia A. Ogasawara et al.
MITOCHONDRION (2016)
Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes
Polina Matre et al.
ONCOTARGET (2016)
Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition
Nathalie Jacque et al.
BLOOD (2015)
A mitochondrial superoxide theory for oxidative stress diseases and aging
Hiroko P. Indo et al.
JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION (2015)
Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia
Regina Jitschin et al.
BLOOD (2014)
Glutamine-driven oxidative phosphorylation is a major ATP source in transformed mammalian cells in both normoxia and hypoxia
Jing Fan et al.
MOLECULAR SYSTEMS BIOLOGY (2013)
Antitumor Activity Of The Glutaminase Inhibitor CB-839 In Hematological Malignances
Francesco Parlati et al.
BLOOD (2013)
Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
Patrick S. Ward et al.
CANCER CELL (2012)
Glucose-Independent Glutamine Metabolism via TCA Cycling for Proliferation and Survival in B Cells
Anne Le et al.
CELL METABOLISM (2012)
Glutaminolysis Activates Rag-mTORC1 Signaling
Raul V. Duran et al.
MOLECULAR CELL (2012)
ATM Is a Redox Sensor Linking Genome Stability and Carbon Metabolism
Antje Krueger et al.
SCIENCE SIGNALING (2011)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
MiR-15a and miR-16-1 cluster functions in human leukemia
George A. Calin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Stressing out over survival: Glutamine as an apoptotic modulator
BC Fuchs et al.
JOURNAL OF SURGICAL RESEARCH (2006)
Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP
K Balakrishnan et al.
BLOOD (2005)
Role of myeloid cell factor-1 (Mcl-1) in chronic lymphocytic leukemia
JB Johnston et al.
LEUKEMIA & LYMPHOMA (2004)
Share Paper
